Top biologic drugs by share of total drug costs in Canadian public plans 2016-2017
Top biologic drugs by share of total drug costs within select Canadian public drug plans in 2016/2017*
This statistic depicts the top biologic drugs by share of total drug costs within select Canadian public drug plans in 2016/2017. Top listed biologic drug was Lucentis with a 2.7 percent share of total drug costs that year.
Top biologic drugs by share of total drug costs within select Canadian public drug plans in 2016/2017*
Source
More information
Statistics on "Canadian pharmaceutical industry"
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- Rx drug expenditure in Canada by plan and type 2016/2017
- Biologics share of total drug costs in Canada by public drug plan 2016/2017
- Level 1 ATC therapy classes by share of total public drug costs in Canada 2016/2017
- Dispensing fee per prescription in Canada by drug plan 2016/2017
- Plan-paid share of Rx drug expenditures in Canada by public plan 2016/2017
- Change of drug cost in Canada by public drug plan 2016/2017
- Generic drug savings by top drug in Canada's public drug plans 2012/2013
- Age of active public drug plan beneficiaries in Canada in 2013/2014
- Share of drug dispensing costs in select public drug plans Canada 2011-2017
- Rx drug expenditure distribution in Canada by public drug plan 2016/2017
- Prescriptions per active beneficiary in Canada by public drug plan 2013/2014
- Drug dispensing cost share by drug type in public drug plans Canada 2014/15-2015/16
- Average Rx drug cost per senior beneficiary in Canada by public drug plan 2015/2016
- Number of public drug plan beneficiaries in Canada by province 2016/2017
- Expenditures dedicated to drugs as share of total health spending in Canada 2005-2017
- Active beneficiary population change in Canadian public drug plans 2016/2017
- Italy: total expenditure on drugs to treat hypertension 2017, by type
- Italy: per capita expenditure on class A ethical drugs 2017, by region
- Projected decrease in brand drug spending due to patent loss in the U.S. 2013-2022
- Citalopram out of pocket price in the U.S. 2004-2016
Statistics on "Canadian pharmaceutical industry"
Related topics
About Statista
